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Selective estrogen receptor modulators (SERMs) reduce the risk of recurrence of invasive breast cancer and the
incidence of first breast cancers in women who are at increased risk. Multiple, randomized clinical trials have shown
both the efficacy and safety of SERMs in reducing the risk of breast cancer. Long-term follow-up as long as 20 years
in the randomized trials shows persistent efficacy with acceptable safety. Hormone replacement therapy given
concurrently with tamoxifen abrogates its preventive effect, but women with atypical hyperplasia derive particular
benefit from SERM therapy. Aromatase inhibitors also reduce the risk of developing invasive breast cancer, but
the experience with them for risk reduction is limited to few trials. National organizations have made recommendations
to use SERMs and aromatase inhibitors to reduce the risk of breast cancer in high-risk women and additional efforts
should be made to increase their use in clinical practice, where the number of women needed to treat to prevent one
case of breast cancer conforms to accepted standards of preventive medicine.
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Breast cancer is due, in part, to the stimulation of initiated
cancer cells by estrogen through the estrogen receptor
(ER). Selective estrogen receptor modulators (SERMs) are
competitive inhibitors of estrogen at the receptor and have
been used effectively for decades to treat both early and
advanced breast cancer. Aromatase inhibitors block the
production of estrogen in postmenopausal women and are
as effective as SERMs in treating both early and advanced
breast cancer. Risk factors, such as family history and be-
nign breast disease, identify women who are at increased
risk for developing breast cancer. Investigators have been
conducting clinical trials with SERMs and aromatase
inhibitors for more than 20 years [1-16]. Cuzick et al. [6]
conducted a meta-analysis based on individual-level data
from nine randomized trials that compared SERMs with
placebo or another drug in women without breast cancer.
The meta-analysis included 83,399 women with 306,617
collective years of follow-up and eight of the analyzed trials
were placebo-controlled trials, whereas one compared tam-
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unless otherwise stated.in breast cancer incidence, with 42 women needing to be
treated to prevent one case of breast cancer, over a 10-year
follow-up period; the largest risk reduction was observed in
the first 5 years. There was also a significant 73% increase
in the incidence of thromboembolic disease with all SERMs
and a significant 34% reduction in the incidence of non-
vertebral fractures, although information about absolute
risks was not available [6]. Long-term follow-up is a useful
expansion of the initial reports that guides clinicians in
weighing the risks and benefits of a preventive risk reduc-
tion intervention.The IBIS-I trial
The IBIS-I trial was one of several prospective trials of a
SERM to reduce the risk of breast cancer in high-risk
women. It was a randomized, controlled trial conducted in
both premenopausal and postmenopausal women aged 35
to 70, randomly assigned to receive oral tamoxifen 20 mg
daily or matching placebo for 5 years [17]. After a median
follow-up of 16 years, 251 breast cancers occurred in
3,579 patients in the tamoxifen group compared with 350
breast cancers in 3,575 women in the placebo group,
representing a 29% reduction in risk. The risk of develop-
ing breast cancer was similar between years 0 to 10 andan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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seen in invasive ER-positive breast cancer (34%) and ductal
carcinoma in situ (35%), but no effect was noted for inva-
sive ER-negative breast cancer.
Importantly, 40% of trial participants in IBIS-I used
menopausal hormone replacement therapy (HRT) at some
time during the treatment phase of the trial. Of potential
interest was a non-statistically significant interaction be-
tween HRT use and tamoxifen that was reported in the
initial results from IBIS-I [8]. Among women who never
used HRT or who used it only before the trial, there was a
statistically significant reduction in ER-positive breast can-
cers in the tamoxifen arm compared with the placebo arm
(51%). However, for women who used HRT at some stage
during the trial, no clear effect of tamoxifen was seen, ei-
ther overall or for ER-positive tumors. Results were similar
regardless of the HRT preparations used, i.e., estrogen
only or combined estrogen and progestin. HRT use was
not associated with the development of ER-negative breast
cancers, either during the active treatment period or the
subsequent period.
Discussion
While the IBIS-I trial data show inhibition of the benefit
of tamoxifen therapy among women taking oral HRT, it is
known that conjugated equine estrogen treatment alone
without a progestin does not increase the incidence of
invasive of breast cancer. In fact, published data show that
conjugated equine estrogen alone reduces the risk of inva-
sive breast cancer in postmenopausal women [18]. We are
not given complete information about what HRT prepara-
tions were used by the women in the trial. The use of
HRT may explain, at least in part, why the reduction of
breast cancer risk in IBIS-I (28% reduction in years 0
to10) was less than that seen in the other reported risk
reduction trials using tamoxifen. The use of conjugated
estrogens alone in IBIS-I may have nevertheless partially
abrogated the potential benefit of tamoxifen.
Given the results from other published risk reduction
trials, it is somewhat surprising that the risk reduction
during the first 10 years of follow-up in IBIS-I was only
29% and increased to just 31% in subsequent years. It is
reassuring that there is a persistent and enduring effect of
tamoxifen: even after 20 years of follow-up, the estimated
risk of developing all types of breast cancer was 12.3% in
the placebo group compared with only 7.8% in the tamoxi-
fen group. These data indicate that the number needed to
treat with 5 years of tamoxifen to prevent one breast can-
cer in the next 20 years was only 22 women. More import-
antly, the risk reduction for ER-positive cancers was
greater, but the number needed to treat and prevent one
case of ER-positive breast cancer was 29 women.
As in other SERM risk reduction trials [19], there was
a significant reduction in ductal carcinoma in situ, whichwas 45% during 0 to 10 years of follow-up but decreased
to only 9% with 10 or more years of follow-up. The re-
duction in the risk for ER-positive cancers during
10 years was 32%, and increased to 37% among women
with 10 or more years of follow-up.
There were more ER-negative breast cancers in the
tamoxifen group of IBIS-I after 10 years of follow-up
than in the placebo group, although the reasons for this
are not obvious. The odds for deep vein thrombosis with
tamoxifen were increased by 73%, but this increased risk
was observed only during the first 10 years of follow-up.
These data are similar to those reported in the Breast
Cancer Prevention Trial [1,2] and the STAR trial [10,11].
The non-significant increase in ER-negative tumors
after 10 years seen in IBIS-I has been attributed by some
observers to a suppression of the appearance of these
tumors while tamoxifen therapy was being administered
followed by a release of the suppression when tamoxifen
therapy ended. This, however, should not be viewed as a
failure of tamoxifen therapy. The large reduction in the
incidence of ER-positive breast cancers significantly
outweighs the small number of ER-negative tumors that
occurred in tamoxifen-treated women.
Although the authors of these long-term data from
IBIS-I state that it is of concern that a reduced incidence
of breast cancer with tamoxifen has not translated into
mortality reduction, they reported that only 9.5% of inci-
dent breast cancer cases have died. They acknowledge that
the power of their analysis for mortality reduction is much
lower than that for incidence and note that the observed
reduction in incidence should have translated to an esti-
mated 18% reduction in breast cancer mortality, but their
statistical power to detect such a reduction in mortality
was only 12% given the small number of deaths that oc-
curred. The trial should not be interpreted, therefore, as
having failed to show a reduction in mortality.
Aromatase inhibitors for reducing the risk of
breast cancer
SERMs are not the only agents known to reduce the risk
of breast cancer in women at increased risk. In the IBIS-II
trial, women were randomly assigned to receive anastro-
zole or placebo [20]. After a median follow-up of 5 years,
2% in the anastrozole group and 4% in the placebo group
developed breast cancer (hazard ratio 0.47, 53% reduction
in incidence). The predicted cumulative incidence of all
breast cancers after 7 years was 5.6% in the placebo group
and 2.8% in the anastrozole group. For women who en-
tered the trial with either lobular carcinoma in situ or
atypical hyperplasia, the risk reduction in the incidence of
invasive breast cancer was 69% after 7 years of therapy. In
the MAP3 trial, 65% fewer invasive breast cancers were
detected in women given the aromatase inhibitor exemes-
tane compared with those women assigned placebo [12].
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risk of breast cancer
In order for a preventive strategy to be both effective
and efficient, we need an easily identified target popula-
tion, criteria for identifying those who would benefit
from a risk reduction strategy, a safe and effective agent,
an informed group of practitioners who can provide care
to the high-risk group, and an educated population of
patients who understand the advantages and the risks of
taking a drug to modify their risk [21].
Freedman et al. [22] developed a benefit/risk index to
quantify benefits from chemoprevention with tamoxifen
or raloxifene, the SERMS used in the NSABP STAR trial.
The benefits and risks of raloxifene and tamoxifen are
described in tables that can help identify groups of
women for whom the benefits outweigh the risks. The
published benefit/risk indices indicate that raloxifene is
better than tamoxifen for women aged 50 years or older
with a uterus. For women without a uterus, the benefit/
risk profile for raloxifene is similar to that for tamoxifen.
It is possible for a health care provider to obtain a bene-
fit/risk index from the published tables, and by combin-
ing this information with that on clinical features and
personal preferences, the provider and patient can make
an informed decision.
Despite the compelling results of chemoprevention trials
using SERMs for breast cancer risk reduction, there has
been minimal use of either tamoxifen or raloxifene by
women at risk for breast cancer. A number of reasons have
been put forth to explain why patients may not be willing
to adopt a SERM for breast cancer risk reduction. HRT is
still widely used by postmenopausal women, even after
published results showed an associated increased risk for
breast cancer, but its use is contraindicated with concurrent
SERM therapy. Patients erroneously perceive the risks of
SERM therapy to be greater than its benefits, and they per-
ceive the risks of therapy-related side effects to be greater
than their risk of breast cancer [16]. This problem is con-
founded by the fact that they (and perhaps their physicians)
are confused by the concept of probabilistic risk. Finally,
they fear endometrial cancer out of proportion to its true
tamoxifen-related risk and do not understand that there is
no increased risk of uterine malignancy associated with
raloxifene; we must hope that lasofoxifene does not soon
suffer the same fate of misinformation. Additional reasons
not to adopt and initiate strategies to reduce the risk of
breast cancer include the fear of adverse effects, medication
costs, lack of reasonably accurate and feasible methods for
assessing personal individual risk, and lack of established
risk thresholds that maximize benefit and minimize harms.
The special case of cellular atypia
A number of studies have indicated that breast cancer risk is
increased following detection of atypical hyperplasia, makingwomen with these lesions ideal candidates for breast cancer
risk reduction [1,2,7,10-12,17,23,24]. Thus, chemoprevention
with a SERM may be particularly beneficial to women with
atypical hyperplasia, a 5-year Gail model risk of more than
5%, lobular carcinoma in situ, or two or more first-degree
relatives with breast cancer based on the published data
reviewed in this chapter. There are no primary prevention
studies to evaluate the optimum duration of tamoxifen ther-
apy for reducing the risk of breast cancer, but completed
clinical trials in the adjuvant therapy setting show that using
tamoxifen for 10 years is more beneficial than only 5 years
of use. No trials are being conducted or are planned to
examine the ideal duration of therapy in the risk-reduction
setting.
Summary and clinical recommendations
Based on all of the available published data, the American
Society of Clinical Oncology (ASCO) recommended, in
2013, that in women at increased risk of breast cancer
aged ≥35 years, tamoxifen (20 mg per day for 5 years)
should be discussed as an option to reduce the risk of ER-
positive breast cancer [25]. In postmenopausal women,
raloxifene (60 mg per day for 5 years) and exemestane
(25 mg per day for 5 years) should also be discussed as
options for breast cancer risk reduction. Those women at
increased breast cancer risk are defined as individuals with
a 5-year projected absolute risk of breast cancer ≥1.66%
(based on the National Cancer Institute Breast Cancer Risk
Assessment Tool or an equivalent measure) or women di-
agnosed with lobular carcinoma in situ. ASCO encouraged
health care providers to discuss the option of chemopre-
vention among women at increased breast cancer risk and
urged that the discussion include the specific risks and
benefits associated with each chemopreventive agent.
Because the risk of clotting increases with age, and be-
cause both stroke and pulmonary embolism are potentially
life-threatening consequences of tamoxifen therapy, care-
ful consideration must be given to risks versus benefits in
older postmenopausal women who are considering tam-
oxifen for risk reduction.
At a minimum, a risk assessment encounter should in-
clude a clear description of the benefits and risks of taking
a SERM for the individual woman, including a description
of the side effects experienced by published study partici-
pants. For example, the counselor should take into account
particular risk factors to see if the woman is subject to in-
creased risk of SERM, aromatase inhibitor-induced stroke,
or endometrial cancer.
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